Clinical Trial Update: NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

View source ↗

Summary

A non-interventional study is investigating the benefits of applying Transjugular Intrahepatic Portosystemic Shunt (TIPS) in hepatocellular carcinoma patients t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Hepatocellular Carcinoma (HCC) | Status: RECRUITING